Charles J. Link, Jr, MD
Chairman of the Board
Charles J. Link Jr, MD, has served as Chief Executive Officer since 2003, and Chairman of the Board of Directors and Chief Scientific Officer since co-founding the company in 1999. Following undergraduate study at the United States Air Force Academy, Dr Link received a BA degree from Stanford University and an MD degree from Stanford University School of Medicine in Stanford, California. He trained in internal medicine at the University of California, San Francisco, and continued fellowship training in medical oncology at the National Cancer Institute in Bethesda, Maryland. Dr Link has authored more than 100 scientific articles and reviews.
Thomas A. Raffin, MD
Thomas A. Raffin, MD, is Lead Director and has served as a member of the Board of Directors since 1999. Dr Raffin spent 30 years on the faculty at Stanford University School of Medicine, where he is the Colleen and Robert Haas Professor Emeritus of Medicine and Biomedical Ethics. Dr Raffin received a BA from Stanford University and an MD from Stanford University School of Medicine and completed his medical residency at the Peter Bent Brigham Hospital (now Brigham and Women’s Hospital) in Boston, Massachusetts.
Paul R. Edick
Paul R. Edick was appointed to the Board of Directors in July 2011. Since July 2010, Mr Edick has been the Chief Executive Officer of Durata Therapeutics, a start-up biopharmaceutical company. Previous positions held include Chief Executive Officer of Ganic Pharmaceuticals, Chief Executive Officer of MedPointe Healthcare Inc., and President of MedPointe Healthcare Inc. Mr Edick holds a BA in Psychology from Hamilton College in Clinton, New York.
Paolo Pucci was appointed to the Board of Directors in November 2015. He is Chief Executive Officer and a Director of ArQule Inc., a clinical-stage biotechnology company that is researching and developing cancer therapeutics. Prior to ArQule, Paolo was Senior Vice President of the Bayer-Schering Pharmaceuticals Global Oncology/Specialized Therapeutics Business Unit at Bayer AG. He also served as an independent director of Dyax Corporation, until it was acquired by Shire Plc, and as an independent director of Algeta ASA, until it was acquired by Bayer AG. Paolo holds an MBA from the University of Chicago Booth School of Business and is a graduate of the Università Degli Studi di Napoli Federico II in Naples, Italy.
Ernest J. Talarico III
Ernest J. Talarico III has served as a member of the Board of Directors since 1999. Mr Talarico has worked for Mesirow Financial Holdings, Inc., a diversified financial services firm headquartered in Chicago, Illinois, since 1998, where he has been a managing director since June 2008. Mr Talarico holds a bachelor’s degree from the University of Iowa in Iowa City, Iowa, as well as licenses in equities, options, and managed futures.
Nicholas N. Vahanian, MD
Nicholas Vahanian, MD, was appointed to the Board of Directors in November 2015. Dr Vahanian has served as President and Chief Medical Officer of NewLink Genetics since 2009. Dr Vahanian began his research career at the National Cancer Institute and continued on to the National Center for Human Genome Research Institute. Dr Vahanian holds a BS in biology from Virginia Commonwealth University in Richmond, Virginia, and an MBA from the University of Notre Dame in Notre Dame, Indiana. He attended St. Bartholomew’s and Royal London Hospital Medical College where he earned his medical degree, and completed a fellowship in molecular oncology at the John Stoddard Cancer Research Institute in Urbandale, Iowa.
Lota S. Zoth
Lota has served as a member of the Board of Directors since November 2012. Lota served as Senior Vice President and Chief Financial Officer of MedImmune, Inc. from April 2004 to July 2007, before which she served as its Controller and Principal Accounting Officer. Lota also served as an auditor at Ernst & Young, LLP and is a Certified Public Accountant. She received a BBA in accounting from Texas Tech University in Lubbock, Texas.